Aquestive Therapeutics was Zevra Therapeutics’s largest revenue line in fiscal 2021, bringing in $20.90M of $28.60M (73%).
| Counterparty Name | FY 2021 |
|---|---|
| Aquestive Therapeutics | $20.90M |
| Corium, Inc | $7.70M |
| Total | $28.60M |
Zevra Therapeutics brought in $28.60M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Aquestive Therapeutics was the largest at $20.90M (73.1%), ahead of Corium, Inc at $7.70M (26.9%).
Previously Reported was Zevra Therapeutics’s largest revenue line in fiscal 2022, bringing in $10.46M of $10.16M (103%).
| Revision of Prior Period | FY 2022 |
|---|---|
| Previously Reported | $10.46M |
| Revision Of Prior Period, Adjustment | -$297.00K |
| Total | $10.16M |
Zevra Therapeutics brought in $10.16M from its two revenue lines in fiscal 2022, the year ended December 31, 2022. Previously Reported was the largest at $10.46M (102.9%).
The total is net of Revision Of Prior Period, Adjustment, which took $297.00K off revenue in fiscal 2022.
Zevra Therapeutics (ZVRA) reports its revenue by counterparty name and by revision of prior period. In fiscal 2021, Aquestive Therapeutics was its largest revenue line, bringing in $20.90M (73.1% of the total), followed by Corium, Inc at $7.70M (26.9%).
Aquestive Therapeutics was Zevra Therapeutics' largest revenue line in fiscal 2021, bringing in $20.90M, or 73.1% of the $28.60M total across its two revenue lines.
Every figure comes from Zevra Therapeutics' annual financial filings, as reported. Each line keeps the name Zevra Therapeutics gives it, and years follow its fiscal calendar.
Zevra Therapeutics' revenue by counterparty name goes back to fiscal 2021, with figures through fiscal 2021. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.